Immuno-Oncology
In this product category, you will find reports and other services providing you with the most uptodate business and competitive intelligence information on immuno-oncology including immune checkpoint inhibitors and activators, and modulators of the tumor-microenvironment. The range of products covers industry data as well as in-depth strategic assessment and analysis of immuno-oncology companies, technologies, targets, R&D pipeline as well as market and sales information.
Subscribe to
our newsletters!
Showing all 8 resultsSorted by latest
-
February of 2025Report with a landscape analysis of PD-(L)1 x VEGF(R) bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective...€ 2000.00
-
August of 2024This product provides basic pipeline information on investigational immunotherapeutics targeting CD47 or SIRP-alpha.€ 400.00
-
March of 2024This product provides basic information on approved and investigational antibodies, cell therapies and small molecules targeting CD38.€ 300.00
-
On the same day of purchaseThis product provides basic information on immunotherapy candidates in research and development targeting B7-H3.€ 300.00
-
On the same day of purchaseThis product provides basic information on therapeutic antibodies in R&D targeting C-C chemokine receptor type 8 (CCR8).€ 300.00
-
On the same day of purchaseThis product provides basic information on drug candidates in research and development targeting CD40 or CD40 ligand€ 300.00
-
May of 2022This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities€ 500.00
-
October of 2021Landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technologies from an industry perspective as of October 2021€ 2250.00